CRYOSTAT-2Randomised controlled trial
CRYOSTAT-2Professor Karim Brohi and Dr Simon Stanworth
CRYOSTAT-2The Queen Mary University of London (QMUL)
CRYOSTAT-2NIHR Health Technology Assessment Board. Grant number: 15/57/02
NHSBT Research Theme
CRYOSTAT-2Patient Blood Management
CRYOSTAT-2A multi-centre, randomised, controlled trial evaluating the effects of early high-dose cryoprecipitate in adult patients with major trauma haemorrhage requiring major haemorrhage protocol (MHP) activation.
CRYOSTAT-2Major bleeding after injury is exacerbated by a clotting abnormality – ‘acute traumatic coagulopathy’ (ATC). ATC is characterised by hypofibrinogenaemia and fibrinolysis. Early replacement of fibrinogen will treat the coagulopathy and may reduce bleeding and improve outcomes. This study will evaluate whether early fibrinogen supplementation in the form of cryoprecipitate (equivalent of 6g fibrinogen replacement) during major traumatic haemorrhage will reduce mortality at 28 days. Secondary outcomes include all-cause mortality up to 12 months, death from bleeding, symbiotic thrombotic events, total transfusion requirements, hospital resource use and quality of life measures.
CRYOSTAT-2Interventional phase III study. Multi-centre, interventional, randomised, unblinded, parallel controlled trial. Participants will be randomised 1:1 via opaque sealed envelopes held securely in participating sites. The study will take place in all 23 Major Trauma Centres in England, as well as International Sites in North America and Australia.